SPRY
ARS Pharmaceuticals, Inc.
$9.4
-0.14
(-1.47%)
| Exchange: | NASDAQ |
| Market Cap: | 923.01M |
| Shares Outstanding: | 33.067M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Richard E. Lowenthal MSMSEL | |||||
| Full Time Employees: | 155 | |||||
| Address: |
|
|||||
| Website: | https://ars-pharma.com |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
